

# Mario Fioravanti

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4170748/publications.pdf>

Version: 2024-02-01

32  
papers

1,585  
citations

623188

14  
h-index

476904

29  
g-index

32  
all docs

32  
docs citations

32  
times ranked

2497  
citing authors

#	ARTICLE	IF	CITATIONS
1	A Meta-Analysis of Cognitive Deficits in Adults with a Diagnosis of Schizophrenia. <i>Neuropsychology Review</i> , 2005, 15, 73-95.	2.5	382
2	Cognitive deficits in schizophrenia: an updated metanalysis of the scientific evidence. <i>BMC Psychiatry</i> , 2012, 12, 64.	1.1	309
3	Memory rehabilitation in Alzheimer's disease: a review of progress. <i>International Journal of Geriatric Psychiatry</i> , 2001, 16, 794-809.	1.3	206
4	Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. <i>The Cochrane Library</i> , 2005, , CD000269.	1.5	120
5	Therapeutic Use of Nicergoline. <i>Clinical Drug Investigation</i> , 2008, 28, 533-552.	1.1	67
6	Systematic review of the body of evidence for the use of biomarkers in the diagnosis of dementia. <i>Alzheimer's and Dementia</i> , 2013, 9, e96-e105.	0.4	66
7	Idebenone in senile dementia of Alzheimer type: A multicentre study. <i>Archives of Gerontology and Geriatrics</i> , 1992, 15, 249-260.	1.4	65
8	Nicergoline for dementia and other age associated forms of cognitive impairment. <i>The Cochrane Library</i> , 2001, , CD003159.	1.5	51
9	Is urinary 1-hydroxypyrene a valid biomarker for exposure to air pollution in outdoor workers? A meta-analysis. <i>Journal of Exposure Science and Environmental Epidemiology</i> , 2014, 24, 17-26.	1.8	46
10	Cadmium and hypertension in exposed workers: A meta-analysis. <i>International Journal of Occupational Medicine and Environmental Health</i> , 2013, 26, 440-56.	0.6	43
11	Citicoline (Cognizin) in the treatment of cognitive impairment. <i>Clinical Interventions in Aging</i> , 2006, 1, 247-251.	1.3	41
12	The Italian version of the Alzheimer's Disease Assessment Scale (ADAS): psychometric and normative characteristics from a normal aged population. <i>Archives of Gerontology and Geriatrics</i> , 1994, 19, 21-30.	1.4	31
13	CBF and cognitive evaluation of Alzheimer type patients before and after IMAO-B treatment: a pilot study. <i>European Neuropsychopharmacology</i> , 1992, 2, 31-35.	0.3	29
14	A systematic review and meta-analysis assessing adverse event profile and tolerability of nicergoline. <i>BMJ Open</i> , 2014, 4, e005090-e005090.	0.8	23
15	Some implications of self versus ideal-self congruence on the revised Adjective Check List.. <i>Journal of Personality and Social Psychology</i> , 1983, 44, 1214-1220.	2.6	15
16	Forgetting curves in long-term memory: Evidence for a multistage model of retention. <i>Brain and Cognition</i> , 1992, 18, 116-124.	0.8	14
17	Long-term idebenone treatment of vascular and degenerative brain disorders of the elderly. <i>Archives of Gerontology and Geriatrics</i> , 1992, 15, 261-269.	1.4	14
18	Chronic Obstructive Pulmonary Disease and Associated Patterns of Memory Decline. <i>Dementia and Geriatric Cognitive Disorders</i> , 1995, 6, 39-48.	0.7	14

#	ARTICLE	IF	CITATIONS
19	Randomized, double-blind, placebo controlled, multicentre study of idebenone in patients suffering from multi-infarct dementia. Archives of Gerontology and Geriatrics, 1992, 15, 239-248.	1.4	10
20	Memory Improvements and Pharmacological Treatment: A Method to Distinguish Direct Effects on Memory from Secondary Effects Due to Attention Improvement. International Psychogeriatrics, 1992, 4, 119-126.	0.6	7
21	The relevance of continuous blood pressure monitoring in examining the relationship of memory efficiency with blood pressure characteristics. Physiology and Behavior, 1996, 59, 1077-1084.	1.0	7
22	Differential characteristics of the aging process and the vascular cognitive impairment in the organization of memory retrieval. Journal of the Neurological Sciences, 2012, 322, 148-151.	0.3	5
23	Monoamine Oxidase and Dementia: Treatment with an Inhibitor of MAO-B Activity. Dementia and Geriatric Cognitive Disorders, 1990, 1, 109-114.	0.7	4
24	Quality of life in chronic diseases of the aged: the importance of cognitive deterioration. Archives of Gerontology and Geriatrics, 1996, 22, 195-205.	1.4	4
25	A multidimensional approach to the assessment of clinical validity in a study on CCVD treatment: dihydroergocristine versus placebo. Archives of Gerontology and Geriatrics, 1987, 6, 83-93.	1.4	3
26	Measuring cognitive processes in patients with parkinson's disease. Archives of Clinical Neuropsychology, 1991, 6, 319-325.	0.3	3
27	History of Symptomatic Therapy in Vascular Dementia. International Psychogeriatrics, 2003, 15, 177-181.	0.6	2
28	Memory rehabilitation in Alzheimer's disease: a review of progress. , 2001, 16, 794.		2
29	Measuring cognitive processes in patients with parkinson's disease. Archives of Clinical Neuropsychology, 1991, 6, 319-325.	0.3	1
30	Relationship between memory, attention, and depression in chronic cerebro-vascular patients. Journal of the Neurological Sciences, 2007, 257, 155-159.	0.3	1
31	Differences between the aging process and the chronic cerebrovascular impairment of memory functioning: the emotional and cognitive interaction. Reviews in the Neurosciences, 2012, 23, 691-6.	1.4	0
32	Authors' response to 'Comments on Sancini et al.'. Occupational Medicine, 2013, 63, 162-162.	0.8	0